Skip to main content
. Author manuscript; available in PMC: 2023 Jul 4.
Published in final edited form as: Clin Cancer Res. 2023 Jan 4;29(1):50–59. doi: 10.1158/1078-0432.CCR-22-2526

Figure 2. Gene expression differences in blood from enrolled patients with treatment duration greater or less than median 21 weeks.

Figure 2.

A) CD19 and PAX5 expression appears to be higher at baseline and decrease with treatment in patients treated longer than median 21 weeks compared to patients treated less than 21 weeks. B) IL1R2, ARG1, and FLT3 expression increases over time in patients with duration of treatment shorter than median 21 weeks but does not in patients with treatment of duration than median 21 weeks.